Three Indian drug makers, and a Netherlands-based firm which has a majority of its plants in the country, are gearing up to make antiviral drug remdesivir, according to a report by the Business Standard. Remdesivir is under consideration for treatment of COVID-19 patients.
These companies — Cipla, Hetero Labs, Jubilant LifeSciences and Dutch firm Mylan — have signed licensing pacts with United States-based Gilead.
Follow our LIVE blog for the latest updates of the novel coronavirus pandemic
Under the licensing agreements, the companies have the right to receive a technology transfer of the Gilead manufacturing process for remdesivir to enable them to scale up production more quickly.